For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...
The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...
U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...
Corcept Therapeutics Incorporated CORT has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024.This company engages in the discovery and development of drugs...
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus Estimate for its...
Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...
For Immediate ReleaseChicago, IL – October 23, 2024 – Stocks in this week’s article are Idaho Strategic Resources Inc. IDR, Qifu Technology Inc. QFIN, Sezzle Inc. SEZL, Corcept Therapeutics Inc....
September and October are known as the most disrupting months on Wall Street. Surprisingly, this year, September was quite favorable for market participants. An aggressive 50 basis-point interest rate...
Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $12 Put had some of the highest...